Merrimack Pharmaceuticals Inc. Announces the Addition of Cancer Research Pioneer John Mendelsohn, M.D. to Its Board of Directors
6/19/2012 9:54:36 AM
CAMBRIDGE, Mass., June 18, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of John Mendelsohn, M.D., past president of The University of Texas MD Anderson Cancer Center to its Board of Directors. Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer.
comments powered by